Share chart Molecular Templates, Inc.
Extended chart
Simple chart
About Molecular Templates, Inc.
Molecular Templates, Inc., биофармацевтическая компания клинической стадии, занимается открытием и разработкой биологических терапевтических средств для лечения рака и других серьезных заболеваний. Компания в первую очередь разрабатывает ряд методов лечения с помощью своей запатентованной лекарственной платформы биологически модифицированных токсинных тел (ETB). more detailsMain settings
| IPO date | 2005-02-04 |
|---|---|
| ISIN | US6085501095 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | link |
| Change price per day: | 0% (0.0001) |
|---|---|
| Change price per week: | 0% (0.0001) |
| Change price per month: | 0% (0.0001) |
| Change price per 3 month: | -80% (0.0005) |
| Change price per half year: | -99.97% (0.3744) |
| Change price per year: | -99.99% (1.26) |
| Change price per 3 year: | -99.99% (0.99) |
| Change price per 5 year: | -100% (16.99) |
| Change price per year to date: | -99.91% (0.1072) |
Grade
Underestimation
| Title | Value | Grade |
|---|---|---|
| P/S | 0.2922 | 10 |
| P/BV | 3.98 | 4 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
|---|---|---|
| ROA, % | -22.96 | 0 |
| ROE, % | -192.88 | 0 |
| ROIC, % | 0 | 0 |
Dividends
| Title | Value | Grade |
|---|---|---|
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
|---|---|---|
| Debt/EBITDA | -3.44 | 10 |
| Debt/Ratio | 0.3456 | 10 |
| Debt/Equity | 7.4 | 0 |
Growth impulse
| Title | Value | Grade |
|---|---|---|
| Yield Revenue, % | 157.32 | 10 |
| Yield Ebitda, % | -102.14 | 0 |
| Yield EPS, % | -1.8 | 0 |
Main owners
| Institutions | Volume | Share, % |
|---|---|---|
| Bellevue Group AG | 1 029 820 | 19.16 |
| BVF Inc. | 532 038 | 9.9 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 354 608 | 6.6 |
| Adage Capital Partners GP L.L.C. | 292 764 | 5.45 |
| Caxton Corporation | 136 866 | 2.55 |
| Vanguard Group Inc | 125 623 | 2.34 |
| Monashee Investment Management LLC | 121 841 | 2.27 |
| Blackrock Inc. | 39 645 | 0.74 |
| Geode Capital Management, LLC | 36 705 | 0.68 |
| Renaissance Technologies, LLC | 23 653 | 0.44 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Eric E. Poma Ph.D. | CEO, Chief Scientific Officer & Director | 923.34k | 1972 (53 years) |
| Ms. Jason S Kim | President, CFO, Treasurer & Principal Accounting Officer | 639.85k | 1975 (50 years) |
| Dr. Joseph Phillips Ph.D. | Senior VP & Head of CMC Development | N/A | |
| Ms. Kristen Quigley B.A. | Chief Operating Officer | N/A | 1971 (54 years) |
| Dr. Grace Kim | Chief Strategy Officer & Head of IR | N/A | |
| Dr. Michelle Iwamoto-Fan J.D., Ph.D. | Senior Vice President & General Counsel | ||
| Dr. Chris Moore Ph.D. | Senior VP and Head of Preclinical Development & Translational Medicine |
About company
Address: United States, Austin. TX, 9301 Amberglen Boulevard - Open in google maps, Open in yandex maps
Website: https://www.mtem.com
Website: https://www.mtem.com
